NDAORALTABLETPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
Isocitrate Dehydrogenase 1 Inhibitors
Pharmacologic Class:
Isocitrate Dehydrogenase 1 Inhibitor
Clinical Trials (2)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Started Oct 2025
408 enrolled
Astrocytoma, IDH-Mutant, Grade 3
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Started Jan 2023
60 enrolled
AstrocytomaOligodendroglioma
Loss of Exclusivity
LOE Date
Jan 16, 2039
156 months away
Patent Expiry
Jan 16, 2039
Exclusivity Expiry
Aug 6, 2031
Company
R-Pharm US
NJ - Princeton